In Central and West Africa, regions together comprising 27 countries and 605 million people, the average person is exposed to particulate pollution levels that are more than 4 times the World Health Organization’s (WHO) guideline of 5 μg/m³1. If these particulate pollution levels persist, averag...e life expectancy in the regions would be 1.6 years lower, and a total of 971 million person-years would be lost, relative to if air quality met the WHO guideline. The Democratic Republic of the Congo, Rwanda and Burundi, are the top three most polluted countries in the region.
more
This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita...ls in the Democratic Republic of the Congo between August 2005 and September 2009 to support the registration of pafuramidine for treatment of first stage HAT in collaboration with the United States Food and Drug Administration. Patients were treated with either 100 mg of pafuramidine orally twice a day for 10 days or 4 mg/kg pentamidine intramuscularly once daily for 7 days to assess the efficacy and safety of pafuramidine versus pentamidine. Pregnant and lactating women as well as adolescents were included.
more
Pregnancy and childbirth during adolescence profoundly affects the lives of millions of girls worldwide, and is a leading cause of maternal mortality and morbidity, and infant and child mortality. Every year, an estimated 21 million girls aged 15–19 years old in low- and middle-income countries be...come pregnant, and approximately 12 million give birth.
For many adolescent girls, the ability to control their sexual lives remains limited. Long-standing gender inequalities and discrimination, marginalization, harmful social and gender norms, and denial of rights, compounded by poverty and violence, render them vulnerable to early pregnancy, HIV and other health threats. Lack of age-appropriate sexual and reproductive health and rights (SRHR) information and services create additional barriers to care and support; as a result, adolescent girls who become pregnant are much more likely to go on to have rapid repeated births.
more
This is the 42nd situation report for the multi-country outbreak of mpox, which provides an update on the epidemiological situation of mpox in Africa (including countries in the WHO African Region and some countries in the WHO Eastern Mediterranean Region), with data as of 3 November 2024.
An example of integration of research into epidemic response.
Important Guideline for Ebola prevention and control
It is designed for the following uses:
- for prevention through preparedness--to help African health facilities make advance preparations for responding with appropriate precautions when a VHF (including Ebola) case is suspected.
- for pl...anning and conducting in-service training to strengthen standard precautions and VHF isolation precautions.
- as a rapid reference when a VHF (i.e. Ebola) case appears at a health facility where no previous VHF preparations have been made.
more
Guidance for health workers
This is only the cover of the book. Download the whole Toolkit at: www.cdc.gov/reproductivehealth/Refugee/
Understanding the reproductive health needs of conflict-affected women will enable organizations to implement and enhance programs and services to improve the health of women and their fam...ilies. The Reproductive Health Assessment Toolkit (RHA) for Conflict-Affected Women provides user-friendly tools to quantitatively assess the reproductive health needs of conflict-affected women aged 15–49 years. The RHA Toolkit enables field staff to collect data to inform program planning, monitoring, evaluation, and advocacy. It promotes using the collected data to enhance services and improve the reproductive health of women and their families.
more
Actualités et réflexions sur la prise en charge médicale du premier patient suspect d’infection par le premier médecin
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
WHO Secretariat Information paper July 2016